Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
Significant Reductions in Frequency and Intensity of Both Bowel Movements and Flushing Episodes Were Observed
Paltusotine was Well-Tolerated with an Overall Pharmacokinetic Profile that was Consistent with Prior Studies
Related news for (CRNX)
- Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
- Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly
- Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer
- Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer
- UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting